EVHNYSEServices-Management ServicesFiscal year ends December 31

Evolent Health, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$4.48−0.09 (-1.97%)

Close on Oct 19, 2026

Market cap: $504.19M
P/E (TTM): –
Dividend yield: –

Evolent Health, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	1,876	2,555	1,964	1,352	908	925	687	627	435	254	97	0	26
Cost of Revenue	1,476	2,187	1,503	1,035	658	697	–	–	–	–	–	–	–
Gross Profit	400	367	460	317	250	228	–	–	–	–	–	–	–
Research & Development	–	–	–	–	16	15	20	18	17	11	5.80	0	2.00
Selling, General & Admin	304	263	358	269	219	210	236	235	206	161	75	0	16
Operating Expenses	–	–	–	–	950	1,192	996	675	508	492	140	0	47
Total Costs & Expenses	2,286	2,595	2,035	1,348	950	1,187	–	–	–	–	–	–	–
Operating Income	-410	-40	-71	3.64	-42	-263	-309	-47	-73	-237	-43	0	-21
Interest Expense	57	25	54	16	25	28	15	5.48	3.64	0.25	0	–	–
Interest & Investment Income	4.19	5.54	5.26	1.37	0.41	2.63	3.41	3.44	1.66	0.97	0.29	–	–
Income from Equity Investments	0.37	-3.44	1.29	4.57	13	10	-9.47	-4.74	-1.76	-0.84	-28	-25	-4.24
Other Non-Operating Income	0.25	0.24	-0.54	0.06	-0.15	-0.12	-0.49	0.11	0.17	0.00	–	–	–
Merger & Restructuring Charges	–	–	–	0	7.32	1.28	0	0	–	–	–	–	–
Asset Impairment Charges	398	0	0	0	0	215	200	0	0	161	0	0	–
Gain (Loss) on Sale of Assets	–	–	-8.11	0	0	-0.70	9.60	0	0	–	–	–	–
Pretax Income	-535	-63	-202	-62	-30	-331	-330	-54	-76	-238	343	-25	20
Income Tax Expense	-0.13	-1.41	-89	-43	0.48	-2.37	-23	0.04	-6.64	-11	23	0	0.01
Income from Continuing Operations	–	-62	-113	-19	-30	-328	-307	–	–	–	–	–	–
Income from Discontinued Operations	–	0	0	-0.46	-7.32	-6.07	1.61	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-579	-93	-142	–	-38	-334	-306	-54	-70	-227	320	-25	20
Minority Interest in Earnings	–	–	–	–	0	0	-3.61	-1.53	-9.10	-67	-13	0	0
Net Income	-535	-62	-113	-19	-38	-334	-302	-53	-61	-160	332	-25	20
Preferred Dividends	–	–	–	–	–	–	–	–	0	0	2.18	5.14	3.66
Net Income to Common	-579	-93	-142	-19	-38	-334	-302	-53	-61	-160	330	-31	2.42
EPS (Basic)(per share)	-5.07	-0.81	-1.28	-0.20	-0.44	-3.94	-3.67	-0.68	-0.94	-3.55	13.14	-13.46	2.51
EPS (Diluted)(per share)	-5.07	-0.81	-1.28	-0.20	-0.44	-3.94	-3.67	-0.68	-0.94	-3.55	6.93	-13.46	0.99
Shares Outstanding (Basic, Weighted)(shares)	114	115	111	94	86	85	82	77	64	45	25	2.31	0.96
Shares Outstanding (Diluted, Weighted)(shares)	114	115	111	94	86	85	82	77	64	45	46	2.31	2.99
EBITDA	-294	78	52	71	18	-201	-248	-2.97	-40	-220	-36	0	-20
Net Interest Income	–	–	–	–	–	–	–	–	–	0.72	0.29	0	-0.82

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 17.2%
Operating margin: -20.4%
Net margin: -24.1%
Return on equity, FY2025: -75.5%

Financial strength

Current ratio: 1.24
Debt to equity: 2.52
Debt to assets: 49.0%
Cash to current liabilities: 23.5%

Valuation

P/E ratio: –
Price to sales: 0.24
Price to book: 1.32
Dividend yield: –